Empowered Funds LLC Has $8.50 Million Stock Position in Insmed, Inc. $INSM

Empowered Funds LLC lifted its holdings in Insmed, Inc. (NASDAQ:INSM) by 32.6% in the 1st quarter, Holdings Channel reports. The firm owned 51,986 shares of the biopharmaceutical company’s stock after buying an additional 12,775 shares during the quarter. Empowered Funds LLC’s holdings in Insmed were worth $8,501,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of INSM. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. Reflection Asset Management bought a new stake in shares of Insmed during the 4th quarter worth about $30,000. Raiffeisen Bank International AG bought a new stake in shares of Insmed during the 4th quarter worth about $32,000. Larson Financial Group LLC increased its holdings in shares of Insmed by 137.0% during the 4th quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 148 shares during the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA acquired a new position in shares of Insmed during the 4th quarter valued at about $49,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on INSM shares. Mizuho set a $192.00 target price on Insmed in a report on Tuesday, June 16th. BMO Capital Markets began coverage on shares of Insmed in a research note on Monday, July 20th. They issued an “outperform” rating and a $192.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, August 10th. Guggenheim lowered their target price on shares of Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $175.00 target price on shares of Insmed in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of “Buy” and an average target price of $205.52.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 21,398 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total value of $2,210,841.36. Following the completion of the transaction, the chief executive officer directly owned 258,917 shares of the company’s stock, valued at $26,751,304.44. This trade represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 6,149 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $108.47, for a total value of $666,982.03. Following the completion of the transaction, the insider directly owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. This trade represents a 12.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 294,440 shares of company stock worth $37,758,548. Insiders own 2.10% of the company’s stock.

Insmed Stock Performance

NASDAQ INSM opened at $123.74 on Friday. The company’s fifty day moving average is $107.88 and its two-hundred day moving average is $128.20. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The firm has a market capitalization of $27.02 billion, a price-to-earnings ratio of -30.11 and a beta of 0.81.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The business had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. During the same quarter last year, the company earned ($1.70) earnings per share. The firm’s revenue was up 296.1% on a year-over-year basis. Equities research analysts forecast that Insmed, Inc. will post -1.83 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.